Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michael F. Emmons
Stat3 Contributes to Resistance Toward BCR-ABL Inhibitors in a Bone Marrow Microenvironment Model of Drug Resistance
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
BCR-ABL Truncation Due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors
Acta Haematologica
Medicine
Hematology
The Secretome Engages STAT3 to Favor a Cytokine-Rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Molecular Cancer Therapeutics
Cancer Research
Oncology
A Non-Atp-Competitive Inhibitor of BCR-ABL Overrides Imatinib Resistance
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
International Journal of Molecular Sciences
Organic Chemistry
Molecular Biology
Theoretical Chemistry
Inorganic Chemistry
Computer Science Applications
Spectroscopy
Medicine
Catalysis
Physical
Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
International Journal of Molecular Sciences
Organic Chemistry
Molecular Biology
Theoretical Chemistry
Inorganic Chemistry
Computer Science Applications
Spectroscopy
Medicine
Catalysis
Physical
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
Galectin-3 Mediates Bone Marrow Microenvironment-Induced Drug Resistance in Acute Leukemia Cells via WNT/Β-Catenin Signaling Pathway
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571
Clinical Cancer Research
Cancer Research
Oncology
